[Watson's biological sales expense rate keeps the industry average and is committed to increasing revenue, reducing expenditure, improving quality and increasing efficiency]
On April 13, Watson Biology (300142) said on the interactive platform that the company's sales expense rate was in line with comparable companies in the same industry. Watson Biology promises to continue to promote related work such as increasing revenue and reducing expenditure, improving quality and increasing efficiency. The enterprise points out that the cost input should be adapted to the company's development stage, strategic layout, market competition and industry maturity.
At present, the market space of China's vaccine industry is large, and the overseas market is also full of opportunities. Is in the stage of market expansion at home and abroad.SpincasinoWatson Biology will increase the investment of resources to ensure the long-term development of the enterprise in the future.
Hexun self-selected stock writer risk tip: the above content is only as the author or guestSpincasinoDoes not represent any position of Hexun and does not constitute any investment advice related to Hexun. Before making any investment decision, investors should consider the risk factors related to investment products according to their own circumstances and consult professional investment advisers if necessary. Hexun tries its best but cannot confirm the authenticity, accuracy and originality of the above content, and Hexun does not make any guarantee or commitment.
